文献速递母胎医学产科

母胎医学会咨询系列第64号:妊娠期系统性红斑狼疮

Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.
PubMed 文献 · Am J Obstet Gynecol · 2022-09-06

系统性红斑狼疮(SLE)是一种慢性多系统炎症性自身免疫病,以复发(俗称「 flare」)和缓解为特征,可累及多个器官,常见肾脏、关节和皮肤受累,育龄期女性妊娠可增加母体并发症风险。本咨询系列旨在审视妊娠并发症并提供妊娠期SLE治疗与管理推荐。

要点

  • SLE孕妇推荐自妊娠12周起使用低剂量阿司匹林至分娩以降低子痫前期发生(GRADE 1B)。
  • 除疾病静止者外,所有SLE孕妇推荐继续或开始羟氯喹(HCQ)治疗(GRADE 1B)。
  • 妊娠期推荐避免长期(>48小时)使用非甾体抗炎药(NSAIDs)(GRADE 1A),并避免COX-2抑制剂和全剂量阿司匹林(GRADE 1B)。

核心结论

  • 本文件旨在审视妊娠并发症并提供SLE妊娠期治疗与管理推荐。
  • SLE患者母体发病率和死亡率显著增加,妊娠期初次诊断SLE与发病率增加相关。

研究设计与样本

  • 母胎医学会(Society for Maternal-Fetal Medicine)咨询系列文件,基于专家意见形成推荐。

主要发现

  • SLE常见并发症包括肾炎、血液学并发症如血小板减少症及多种神经系统异常。
  • SLE孕妇推荐自妊娠12周起使用低剂量阿司匹林至分娩以降低子痫前期发生(GRADE 1B)。
  • 除疾病静止者外,所有SLE孕妇推荐继续或开始羟氯喹(HCQ)治疗(GRADE 1B)。
  • 对于疾病静止且未使用HCQ或其他药物的患者,建议(弱推荐)与风湿科医生协商共同决策是否启用该药(GRADE 2B)。
  • 妊娠期推荐避免长期(>48小时)使用非甾体抗炎药(NSAIDs)(GRADE 1A),并避免COX-2抑制剂和全剂量阿司匹林(GRADE 1B)。

关键数值与推荐

  • 推荐SLE孕妇自妊娠12周起使用低剂量阿司匹林至分娩以降低子痫前期发生(GRADE 1B)。
  • 推荐除疾病静止者外所有SLE孕妇继续或开始羟氯喹(HCQ)治疗(GRADE 1B)。
  • 建议(弱推荐)疾病静止且未用药者与风湿科医生共同决策是否启用HCQ(GRADE 2B)。
  • 推荐妊娠期避免长期(>48小时)使用NSAIDs(GRADE 1A),避免COX-2抑制剂和全剂量阿司匹林(GRADE 1B)。
  • 推荐甲氨蝶呤停用1-3个月、吗替麦考酚酯/霉酚酸至少停用6周后再尝试妊娠(GRADE 1A)。

临床怎么用

  • SLE孕妇推荐自妊娠12周起使用低剂量阿司匹林至分娩以降低子痫前期发生(GRADE 1B)。
  • 除疾病静止者外,所有SLE孕妇推荐继续或开始羟氯喹(HCQ)治疗(GRADE 1B)。
  • 妊娠期推荐避免长期(>48小时)使用NSAIDs(GRADE 1A),避免COX-2抑制剂和全剂量阿司匹林(GRADE 1B)。
  • 推荐甲氨蝶呤停用1-3个月、吗替麦考酚酯/霉酚酸至少停用6周后再尝试妊娠(GRADE 1A)。
  • 推荐SLE孕妇进行产前监测和系列生长超声,因胎儿生长受限(FGR)和死产风险增加(GRADE 1B)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic lupus erythematosus (SLE) is a chronic, multisystem, inflammatory autoimmune disease characterized by relapses (commonly called "flares") and remission. Many organs may be involved, and although the manifestations are highly variable, the kidneys, joints, and skin are commonly affected. Immunologic abnormalities, including the production of antinuclear antibodies, are also characteristic of the disease. Maternal morbidity and mortality are substantially increased in patients with systemic lupus erythematosus, and an initial diagnosis of systemic lupus erythematosus during pregnancy is associated with increased morbidity. Common complications of systemic lupus erythematosus include nephritis, hematologic complications such as thrombocytopenia, and a variety of neurologic abnormalities. The purpose of this document is to examine potential pregnancy complications and to provide recommendations on treatment and management of systemic lupus erythematosus during pregnancy. The following are the Society for Maternal-Fetal Medicine recommendations: (1) we recommend low-dose aspirin beginning at 12 weeks of gestation until delivery in patients with systemic lupus erythematosus to decrease the occurrence of preeclampsia (GRADE 1B); (2) we recommend that all patients with systemic lupus erythematosus, other than those with quiescent disease, either continue or initiate hydroxychloroquine (HCQ) in pregnancy (GRADE 1B); (3) we suggest that for all other patients with quiescent disease activity who are not taking HCQ or other medications, it is reasonable to engage in shared decision-making regarding whether to initiate new therapy with this medication in consultation with the patient's rheumatologist (GRADE 2B); (4) we recommend that prolonged use (>48 hours) of nonsteroidal antiinflammatory drugs (NSAIDs) generally be avoided during pregnancy (GRADE 1A); (5) we recommend that COX-2 inhibitors and full-dose aspirin be avoided during pregnancy (GRADE 1B); (6) we recommend discontinuing methotrexate 1-3 months and mycophenolate mofetil/mycophenolic acid at least 6 weeks before attempting pregnancy (GRADE 1A); (7) we suggest the decision to initiate, continue, or discontinue biologics in pregnancy be made in collaboration with a rheumatologist and be individualized to the patient (GRADE 2C); (8) we suggest treatment with a combination of prophylactic unfractionated or low-molecular-weight heparin and low-dose aspirin for patients without a previous thrombotic event who meet obstetrical criteria for antiphospholipid syndrome (APS) (GRADE 2B); (9) we recommend therapeutic unfractionated or low-molecular-weight heparin for patients with a history of thrombosis and antiphospholipid (aPL) antibodies (GRADE 1B); (10) we suggest treatment with low-dose aspirin alone in patients with systemic lupus erythematosus and antiphospholipid antibodies without clinical events meeting criteria for antiphospholipid syndrome (GRADE 2C); (11) we recommend that steroids not be routinely used for the treatment of fetal heart block due to anti-Sjögren's-syndrome-related antigen A or B (anti-SSA/SSB) antibodies given their unproven benefit and the known risks for both the pregnant patient and fetus (GRADE 1C); (12) we recommend that serial fetal echocardiograms for assessment of the PR interval not be routinely performed in patients with anti-SSA/SSB antibodies outside of a clinical trial setting (GRADE 1B); (13) we recommend that patients with systemic lupus erythematosus undergo prepregnancy counseling with both maternal-fetal medicine and rheumatology specialists that includes a discussion regarding maternal and fetal risks (GRADE 1C); (14) we recommend that pregnancy be generally discouraged in patients with severe maternal risk, including patients with active nephritis; severe pulmonary, cardiac, renal, or neurologic disease; recent stroke; or pulmonary hypertension (GRADE 1C); (15) we recommend antenatal testing and serial growth scans in pregnant patients with systemic lupus erythematosus because of the increased risk of fetal growth restriction (FGR) and stillbirth (GRADE 1B); and (16) we recommend adherence to the Centers for Disease Control and Prevention medical eligibility criteria for contraceptive use in patients with systemic lupus erythematosus (GRADE 1B).

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Silver R, Craigo S, Porter F, et al. Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy. Am J Obstet Gynecol. 2022. PMID: 36084704. doi:10.1016/j.ajog.2022.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。